NEW YORK (360Dx) – Over the next year and a half, Bio-Rad Laboratories plans to add new solutions to bolster its burgeoning blood typing business. 

Over the past year and a half, Bio-Rad Laboratories has obtained US Food and Drug Administration clearance for new instruments targeting the US immunohematology blood typing market. During the next 18 months, the firm plans to round out its suite of with two additional instruments to meet different user needs, a company official said.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.